Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

243.59
+2.761.15%
Post-market: 243.660.0700+0.03%16:31 EDT
Volume:602.19K
Turnover:146.44M
Market Cap:15.81B
PE:16.65
High:244.36
Open:242.93
Low:241.76
Close:240.83
52wk High:266.38
52wk Low:124.47
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.99
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.29
PE(LYR):-41.71

Loading ...

Jazz Pharmaceuticals Plc : Deutsche Bank Raises Target Price to $270 from $250

THOMSON REUTERS
·
Jul 09

Jazz Pharmaceuticals price target lowered to $254 from $256 at Truist

TIPRANKS
·
Jul 07

Jazz Pharmaceuticals is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

Jazz Pharma Director Bruce C. Cozadd Disposes of 6,000 Shares for $1.44 Million

Reuters
·
Jul 07

Jazz Pharmaceuticals Investors Eye Ziihera Launch in GEA as Key Driver, UBS Says

MT Newswires Live
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)

TIPRANKS
·
Jul 01

Jazz Pharma director Mark Douglas Smith disposes of 1,157 shares worth $266,146.35

Reuters
·
Jun 18

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Reuters
·
Jun 17

Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Dow Jones
·
Jun 17

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

TIPRANKS
·
Jun 17

Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers

Reuters
·
Jun 17

Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration

THOMSON REUTERS
·
Jun 17

Jazz announces eleven presentations at SLEEP 2026

TIPRANKS
·
Jun 17

BRIEF-Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data At Sleep 2026, Demonstrating Real-World Impact Of Xywav

Reuters
·
Jun 17

Jazz Pharma says Phase 4 XYLO study shows cardiometabolic risk markers improve after switch to low-sodium Xywav

Reuters
·
Jun 17

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at Sleep 2026, Demonstrating Real-World Impact of Xywav® (Calcium, Magnesium, Potassium, and Sodium Oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

THOMSON REUTERS
·
Jun 17

Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jun 16

How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint

Simply Wall St.
·
Jun 16